Moneycontrol
HomeNewsBusinessEconomyCentre may consider extending deadline to avail 15% corporate tax benefit: Report
Trending Topics

Centre may consider extending deadline to avail 15% corporate tax benefit: Report

FM Sitharaman was speaking to representatives at an industry chamber webinar on June 8.

June 11, 2020 / 09:30 IST
Story continues below Advertisement

Finance Minister Nirmala Sitharaman said the government may consider extending the deadline of 15 percent corporate tax benefit for companies that make new investments in manufacturing.

“I will see what can be done… and I take your point for considering an extension in the deadline of March, 31, 2023,” Sitharaman told industry representatives.

Story continues below Advertisement

The finance minister further clarified that the Emergency Credit Facility for COVID-19 covers “all companies, not just micro, small and medium enterprises” (MSMEs). She added that liquidity issues have been “fairly, clearly addressed”.

Sitharaman also said that all government departments have been asked to clear dues, failure of which can be brought to the Centre’s notice for further action: “If there is any issue with any department, the government will look into it. We are committed to support/intervene.”

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show